Guardant Health GH
Nasdaq · Services-Medical Laboratories · $19.2BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $373.7M | $449.5M | $563.9M | $739.0M | $982.0M | +32.9% | +27.3% | |
| Cost of Revenue (COGS) | — | — | $227.1M | $289.8M | $349.0M | +20.4% | +24.0% | |
| Research & Development (R&D) | $263.2M | $373.8M | $367.2M | $347.8M | $364.2M | +4.7% | +8.5% | |
| Operating Income (EBIT) | $-411.0M | $-544.4M | $-564.7M | $-443.6M | $-437.2M | +1.4% | — | |
| Interest Expense | $2.6M | $2.6M | $2.6M | $2.6M | $3.9M | +51.0% | +10.9% | |
| Income Tax Expense | $300,000 | $1.1M | $685,000 | $1.3M | $-1.3M | −198.4% | — | |
| GAAP Net Income | $-384.8M | $-654.6M | $-479.4M | $-436.4M | $-416.3M | +4.6% | — | |
| Diluted EPS | $-4.00 | $-6.41 | $-4.28 | $-3.56 | $-3.32 | +6.7% | — | |
| Diluted Shares | 101.3M | 102.2M | 112.0M | 122.7M | 125.4M | +2.1% | +5.5% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $492.3M | $141.9M | $1.1B | $629.8M | $489.4M | −22.3% | −0.1% | |
| Inventory | $30.7M | $51.6M | $61.9M | $71.1M | $85.9M | +20.8% | +29.4% | |
| Total Current Assets | $1.1B | $1.2B | $1.3B | $1.1B | $1.5B | +38.9% | +7.1% | |
| Total Assets | $2.2B | $1.6B | $1.8B | $1.5B | $2.0B | +35.5% | −2.2% | |
| Total Current Liabilities | $194.7M | $193.2M | $205.9M | $225.6M | $302.7M | +34.2% | +11.7% | |
| Total Debt (Short + Long Term) | $1.5B | $1.5B | $1.5B | $1.1B | $1.5B | +31.6% | +0.0% | |
| Total Liabilities | $1.6B | $1.5B | $1.6B | $1.6B | $2.1B | +30.0% | +7.9% | |
| Stockholders' Equity | $645.0M | $60.2M | $158.7M | $-139.6M | $-99.3M | +28.9% | — | |
| Net Cash / (Net Debt) | $-1.0B | $-1.4B | $-368.7M | $-512.8M | $-1.0B | −97.9% | — | |
| Invested Capital | $1.7B | $1.4B | $527.4M | $373.1M | $915.3M | +145.3% | −13.8% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $-209.0M | $-309.5M | $-325.0M | $-239.9M | $-184.8M | +23.0% | — | |
| Depreciation & Amortization (D&A) | $22.3M | $36.0M | $42.9M | $42.4M | $39.7M | −6.3% | +15.6% | |
| Stock-Based Compensation (SBC) | $151.4M | $94.7M | $90.8M | $140.4M | $166.2M | +18.4% | +2.4% | |
| Capital Expenditures (CapEx) | $75.0M | $77.5M | $20.5M | $35.1M | $48.3M | +37.7% | −10.4% | |
| Free Cash Flow (FCF) | $-284.1M | $-386.9M | $-345.5M | $-274.9M | $-233.1M | +15.2% | — | |
| True FCF (ex-SBC Owner Cash) | $-435.5M | $-481.6M | $-436.2M | $-415.4M | $-399.3M | +3.9% | — | |
| Share Repurchases (Buybacks) | — | — | $0 | $0 | $45.0M | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.